Dose-related bronchodilator response to aerosolized salbutamol (albuterol) in ventilator-dependent premature infants

J Pediatr. 1992 Jun;120(6):974-9. doi: 10.1016/s0022-3476(05)81973-0.


We used a placebo-controlled standardized protocol to define the dose-response relationship to the beta-adrenergic bronchodilator salbutamol (albuterol) in 10 ventilator-dependent premature infants at a postnatal age of 13.3 +/- 4.9 days. Passive respiratory system resistance and compliance were measured at baseline and 10 minutes after administration of salbutamol via a metered-dose inhaler and spacer device. Salbutamol caused a significant dose-related response with a 33% mean decrease in respiratory system resistance (p less than 0.05) and a 67% mean increase in respiratory system compliance (p less than 0.001). In seven and six patients, respectively, 100 micrograms of salbutamol caused significant improvement in resistance and compliance; 200 micrograms was required in the remainder, but one patient had no improvement in compliance. Oxygen saturation increased linearly with the increase in compliance. In 7 of the 10 infants, the duration of action of 200 micrograms of salbutamol on the following day was 3 hours. We conclude that bronchodilator treatment may be useful in the management of ventilator-dependent neonates with respiratory distress syndrome.

MeSH terms

  • Aerosols
  • Albuterol / administration & dosage
  • Albuterol / therapeutic use*
  • Bronchoconstriction / drug effects*
  • Bronchopulmonary Dysplasia / therapy*
  • Dose-Response Relationship, Drug
  • Humans
  • Infant, Newborn
  • Respiration, Artificial*
  • Respiratory Distress Syndrome, Newborn / therapy*
  • Respiratory Mechanics / drug effects


  • Aerosols
  • Albuterol